For decades, one of the most standardized practices in medical and scientific research has been the use of placebos. No, we’re not talking about the 2000s alt-rock band. We’re talking about a method that, despite its admitted flaws, has for years allowed researchers to study the effects of various substances.
However, today this practice faces a challenge that is forcing science to rethink its mechanisms: psychedelic-assisted therapy.
How a Placebo Works (and How It Doesn’t)
Basically, a placebo is a little deception in pill form. In clinical trials, patients are divided into two groups: one is given the drug under investigation and the other a placebo (which could be, for example, a sugar pill). The catch? The patient doesn’t know which group they belong to. This way, the effectiveness of the drug is compared with a control group.
But things do get complicated: sometimes, patients who have received a placebo, experience effects or improvements whose cause can only be explained psychologically, where expectation plays a role that transcends the mental and produces tangible effects in the physical realm. This is the famous placebo effect.
Now, this methodology opens a Pandora’s box of ethical dilemmas, intensely debated in the scientific community. Is it right to deceive patients this way when they may be expecting to receive a potentially life-saving medicine? Are patient autonomy and rights, not to mention their safety, being ignored? Doesn’t this practice damage trust in medicine as an institution?
All these questions have been circulating in academic circles for years, extending beyond the field of traditional medicine to become relevant in the field of psychedelics. Clinical research with these substances tends to follow the same format as studies of traditional drugs, including randomized placebo trials. If you’re familiar with psychedelics, you’ …
Read More
Author: Marian Venini / High Times
